MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease…
MaaT PharmaJuly 2, 2025
June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…
MaaT PharmaJune 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…
MaaT PharmaJune 2, 2025
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…
MaaT PharmaMay 14, 2025
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive…
MaaT PharmaMay 13, 2025
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…
MaaT PharmaApril 28, 2025
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…
MaaT PharmaMarch 31, 2025
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024…
MaaT PharmaMarch 27, 2025
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…
MaaT PharmaMarch 18, 2025
